help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iveson, T. J.
Right arrow Articles by Dowsett, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iveson, T. J.
Right arrow Articles by Dowsett, M.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 324-331, Copyright © 1993 by Endocrine Society

ARTICLES

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

TJ Iveson, IE Smith, J Ahern, DA Smithers, PF Trunet and M Dowsett
Breast Unit, Royal Marsden Hospital, London, United Kingdom.

We have performed a phase I study of the effect of a single dose of CGS 20267, an oral nonsteroidal aromatase inhibitor, in 12 healthy volunteer postmenopausal women. Each subject received 2 single doses of CGS 20267 (0.1, 0.5, or 2.5 mg) or placebo separated by a washout period of at least 6 weeks. There was statistically significant suppression of serum estrone and estradiol at all three doses of CGS 20267 tested. Serum estrone and estradiol concentrations were maximally suppressed by 76% and 79% from baseline levels, respectively. Urinary excretion of estrone and estradiol was also suppressed, although this did not reach statistical significance. Serum concentrations of aldosterone, cortisol, 17 alpha-hydroxyprogesterone, androstenedione, testosterone, FSH, LH, and TSH were unaffected by CGS 20267. The drug was well tolerated, with no significant side-effects. This study has shown CGS 20267 to be a potent and specific aromatase inhibitor, and further studies are now needed to assess its clinical efficacy.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Handelsman
The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tominaga, I. Adachi, Y. Sasaki, T. Tabei, T. Ikeda, Y. Takatsuka, M. Toi, T. Suwa, and Y. Ohashi
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
Ann. Onc., January 1, 2003; 14(1): 62 - 70.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Buzdar and A. Howell
Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer
Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635.
[Full Text] [PDF]

Home page
 JCOHome page
A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang, and C. Brady
Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate
J. Clin. Oncol., July 15, 2001; 19(14): 3357 - 3366.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
New aromatase inhibitors for breast cancer
DTB, July 1, 1997; 35(7): 55 - 56.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society